BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. J Hepatol 2021;75:706-17. [PMID: 34051332 DOI: 10.1016/j.jhep.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kong F, Li Q, Zhang F, Li X, You H, Pan X, Zheng K, Tang R. Sirtuins as Potential Therapeutic Targets for Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:751516. [PMID: 34708060 DOI: 10.3389/fmed.2021.751516] [Reference Citation Analysis]
2 Shoukry NH, Walker CM. T cell responses during HBV and HCV infections: similar but not quite the same? Curr Opin Virol 2021;51:80-6. [PMID: 34619514 DOI: 10.1016/j.coviro.2021.08.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cheng K, Chen Y, Wang X, Xu M, Liao W, Duan X, Zhao X, Sun Y, Duan Z, Wang L. Entecavir combined with interferon-α is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Cancer 2021. [PMID: 34623636 DOI: 10.1002/cncr.33949] [Reference Citation Analysis]
4 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
6 Söderlund-Venermo M, Varma A, Guo D, Gladue DP, Poole E, Pujol FH, Pappu H, Romalde JL, Kramer L, Baz M, Venter M, Moore MD, Nevels MM, Ezzikouri S, Vakharia VN, Wilson WC, Malik YS, Shi Z, Abdel-Moneim AS. World Society for Virology first international conference: Tackling global virus epidemics. Virology 2022;566:114-21. [PMID: 34902730 DOI: 10.1016/j.virol.2021.11.009] [Reference Citation Analysis]
7 Hsu PK, Su PY, Wu CL. Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B. BMC Gastroenterol 2022;22:228. [PMID: 35538425 DOI: 10.1186/s12876-022-02317-7] [Reference Citation Analysis]